Novagant on Track to Expand Cannabidiol Product Li
Post# of 7004
Posted On: 07/15/2014 5:00:05 PM
Novagant on Track to Expand Cannabidiol Product Line
2014-07-15 16:05 ET - News Release
DENVER, CO -- (Marketwired) -- 07/15/14
Novagant, Inc. (PINKSHEETS: NVGT). The Company is pleased to update its shareholders and supporters that it is aggressively in the process of expanding its Cannabidiol (CBD) product line as a follow-up to its recent announcements of its GLAVAPE™ (Generally Legal American Vape) medical cannabis vaporizer product based on CBD-rich hemp oil and of its newly launched E-Commerce portal website for its new GLAVAPE™ product at www.glavape.com.
The company has been developing its legal hemp product line and marketing strategies for its points of entry for retail sales to take advantage of a potential $8.4 billion medical cannabis industry.
"We at the Company have been busy developing our hemp oil product line of which the GLAVAPE™ was our first to be introduced," says Michael Thornton, Novagant's Vice-President. "Please stay tuned for further announcements on our product development and marketing."
About Novagant, Inc.
Novagant, Inc. was incorporated in the state of Nevada on February 23, 1987 under the name of Kendrex Systems, Inc. The Company underwent several name changes, and ultimately on November 26, 2013 changed its name to Novagant, Inc. For more information about the Company, please visit www.novagant.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact:
Novagant, Inc.
office@novagant.com
2014-07-15 16:05 ET - News Release
DENVER, CO -- (Marketwired) -- 07/15/14
Novagant, Inc. (PINKSHEETS: NVGT). The Company is pleased to update its shareholders and supporters that it is aggressively in the process of expanding its Cannabidiol (CBD) product line as a follow-up to its recent announcements of its GLAVAPE™ (Generally Legal American Vape) medical cannabis vaporizer product based on CBD-rich hemp oil and of its newly launched E-Commerce portal website for its new GLAVAPE™ product at www.glavape.com.
The company has been developing its legal hemp product line and marketing strategies for its points of entry for retail sales to take advantage of a potential $8.4 billion medical cannabis industry.
"We at the Company have been busy developing our hemp oil product line of which the GLAVAPE™ was our first to be introduced," says Michael Thornton, Novagant's Vice-President. "Please stay tuned for further announcements on our product development and marketing."
About Novagant, Inc.
Novagant, Inc. was incorporated in the state of Nevada on February 23, 1987 under the name of Kendrex Systems, Inc. The Company underwent several name changes, and ultimately on November 26, 2013 changed its name to Novagant, Inc. For more information about the Company, please visit www.novagant.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact:
Novagant, Inc.
office@novagant.com
(0)
(0)
